TSRO Share Price

Open 147.60 Change Price %
High 148.51 1 Day 0.98 0.67
Low 143.57 1 Week 11.58 8.51
Close 147.59 1 Month -4.29 -2.82
Volume 596630 1 Year 106.15 256.15
52 Week High 192.94
52 Week Low 36.68
TSRO Important Levels
Resistance 2 152.17
Resistance 1 150.28
Pivot 146.56
Support 1 144.90
Support 2 143.01
NASDAQ USA Most Active Stocks
ASTI 0.00 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
INTC 36.15 -3.42%
INTC 36.15 -3.42%
INTC 36.15 -3.42%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
More..
NASDAQ USA Top Gainers Stocks
SPIR 0.02 100.00%
LOCM 0.09 50.00%
MYRX 0.08 33.33%
STRT 32.15 30.16%
WRES 0.09 28.57%
TBBK 6.45 27.47%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
EHTH 14.18 20.78%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
LLEN 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
ROSE 10.35 -48.20%
ROSE 10.35 -48.20%
DVOX 0.05 -44.44%
More..

TESARO, Inc. (NASDAQ: TSRO)

TSRO Technical Analysis 1.5
As on 28th Apr 2017 TSRO Share Price closed @ 147.59 and we RECOMMEND Buy for LONG-TERM with Stoploss of 119.77 & Sell for SHORT-TERM with Stoploss of 161.56 we also expect STOCK to react on Following IMPORTANT LEVELS.
TSRO Target for April
1st Target up-side 180.3
2nd Target up-side 198.83
3rd Target up-side 217.36
1st Target down-side 127.44
2nd Target down-side 108.91
3rd Target down-side 90.38
TSRO Other Details
Segment EQ
Market Capital 430751968.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.tesarobio.com
TSRO Address
TSRO
1000 Winter Street
Suite 3300
Waltham, MA 02451
United States
Phone: 339-970-0900
Interactive Technical Analysis Chart TESARO, Inc. ( TSRO NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on TESARO, Inc.
TSRO Business Profile
TESARO, Inc. (TESARO) is a development-stage, oncology-focused biopharmaceutical company for cancer patients. The Company focuses on rolapitant and TSR-011 product. The Company�s marketed products and product candidates in development treat cancer through non-specific damage to cellular components or alter cell metabolism or internal repair mechanisms to the demise of cancer cells. Rolapitant is a potent and long-acting neurokinin-1, or NK-1, receptor antagonist is in Phase III clinical trials for the prevention of chemotherapy induced nausea and vomiting (CINV). TSR-011 is an orally available anaplastic lymphoma kinase (ALK), inhibitor (targeted anti-cancer agent) is in preclinical development.